|
|
Newsroom
13/08/2008
Full Year Results for 2008
CSL Limited today announced a profit after tax of $702 million for the twelve months ended 30 June 2008, up 30% when compared to the twelve months ended 30 June 2007. On a constant currency basis profit grew 45%.
More.
17/06/2008
CSL Receives TGA Approval to Register Panvax®, Avian Flu Vaccine
CSL Limited announced today that it has received approval from the Australian Therapeutic Goods Administration (TGA) to register Panvax®, CSL’s avian influenza vaccine. Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus.
More.
20/02/2008
CSL Half Year Results Announcement for 2007/08
CSL Limited today announced a profit after tax of $349 million for the six months ended 31 December 2007, up 36% when compared to the six months ended 31 December 2006. This included an adverse foreign currency impact of $28m, when compared with the prior comparable period (PCP).
More.
14/02/2008
CSL Limited Warns Shareholders of Unsolicited Share Offers
CSL Limited has become aware of unsolicited offers to shareholders to
purchase their shares for a price which significantly undervalues their holding. CSL has advised shareholders, on receipt of such an offer, that they check it carefully.
More.
>>
Prior Archived Newsroom Media EnquiriesDr Rachel David
Director of Public Affairs
Phone: +61 401 775 779
Email:
rachel.david@csl.com.au
45 Poplar Rd
Parkville
Victoria 3052
Australia | Christine Kuhinka
Phone: +1 610 878 4387
Fax: +1 610 878 4584
Email:
christine.kuhinka@cslbehring.com
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901
USA |
|